1. Introduction

Biohybrid Consciousness-Market Regulation in Russia is an emerging interdisciplinary legal subject concerning the regulation of technologies that combine living biological systems with artificial intelligence, neural interfaces, computational systems, robotics and potentially consciousness-related functions.

A biohybrid system may combine:

Living human or animal neural cells with electronic devices.

Brain organoids connected to computer systems.

Biological neurons integrated with artificial intelligence.

Neural implants capable of interpreting or stimulating brain activity.

Biological computing systems used in medical, commercial or research applications.

The central legal question is:

Can consciousness-related biological technology become a commercial market, and who should control its development, ownership, use, sale and commercialization?

Russia does not currently have a separate statute called the Biohybrid Consciousness-Market Regulation Act. The subject must therefore be examined through existing Russian constitutional law, civil law, medical regulation, personal-data protection, biotechnology regulation, intellectual-property law and criminal law.

2. Legal framework governing biohybrid technologies in Russia

Russia does not regulate biohybrid consciousness as one independent legal category. Several existing legal frameworks may apply simultaneously.

The legal significance is that a biohybrid product may be regulated as a medical device, biomedical product, research technology, data-processing system or commercial service, depending on its characteristics and intended use.

3. Constitutional protection of consciousness and human dignity

The Russian Constitution provides the foundation for regulating consciousness-related technologies.

Relevant constitutional provisions include:

Article 20: Right to life.

Article 21: Protection of human dignity and prohibition of treatment that degrades human dignity.

Article 22: Right to liberty and personal inviolability.

Article 23: Privacy and protection of personal and family secrets.

Article 24: Restrictions on collecting, storing, using and disseminating information about private life without consent, subject to constitutional and legal requirements.

Article 41: Right to healthcare and medical assistance.

These provisions become important when companies develop technologies that interact with the human nervous system.

For example, suppose a Russian technology company develops a neural implant that records brain activity and converts neurological signals into commercial data.

Potential legal questions include:

Can the company commercially exploit information generated by the patient's brain?

Can the company sell neurological information to advertisers?

Can an implant manufacturer remotely disable a device?

Can a patient withdraw consent after neural data have been collected?

Can a company claim ownership over biological neural activity?

The constitutional framework supports the protection of personal dignity, privacy and bodily autonomy. It does not, however, expressly establish a separate legal personality or independent property right for consciousness.

4. Medical consent and biohybrid experimentation

One of the most important legal instruments is Federal Law No. 323-FZ of 21 November 2011, concerning the foundations of healthcare protection in Russia.

Article 20 establishes informed voluntary consent as a necessary preliminary condition for medical intervention.

The patient must receive accessible information concerning:

The purpose of the intervention.

The methods being used.

Associated medical risks.

Alternative treatments.

Possible consequences.

Expected medical results.

The legislation also recognizes the right to refuse medical intervention, subject to statutory exceptions.

minzdrav.gov.ru+1

Application to biohybrid consciousness markets

Imagine a medical research institution developing a brain-computer interface connected to living neuronal tissue.

The institution cannot treat the patient's consent as unlimited permission to conduct every future experiment.

A legally meaningful consent process should distinguish:

Therapeutic use.

Experimental use.

Commercial exploitation.

Neural-data collection.

Artificial stimulation of neural activity.

Transfer of information to third parties.

A patient who agrees to receive a medical implant should not automatically be treated as having agreed to commercial exploitation of their neural information.

5. Commercial ownership of biological consciousness

A major difficulty concerns the distinction between ownership of technology and ownership of biological material.

Article 128 of the Russian Civil Code recognizes property, services, intellectual property and non-material benefits as objects of civil rights.

consultant.ru+1

This creates several distinct legal categories.

Important distinction: Ownership of a neural device does not mean ownership of the patient's brain, thoughts, identity or consciousness.

Commercial exploitation of neural information

A technology company might generate revenue through:

Neural-interface subscriptions.

Cognitive rehabilitation services.

Brain-signal analytics.

Neurotechnology licensing.

AI-assisted neurological diagnosis.

Research collaborations.

These commercial activities may be lawful when they comply with applicable medical, contractual, privacy and intellectual-property requirements.

However, a commercial contract cannot automatically convert a person's consciousness into an ordinary transferable commodity.

6. Protection of neural and biometric data

Federal Law No. 152-FZ of 27 July 2006 on Personal Data is particularly relevant to the commercial use of neural information.

Articles 10 and 11 regulate special categories of personal data and biometric personal data.

Article 11 generally requires written consent for processing biometric personal data used to identify an individual, subject to statutory exceptions. Article 10 establishes additional restrictions on processing specified sensitive personal data, including health information.

Минтруд России+1

In biohybrid markets, relevant information could include:

Brainwave recordings.

Neural activity patterns.

Medical information generated by brain implants.

Neurological identification signals.

Cognitive-response measurements.

Information connecting neural activity with an identifiable individual.

Not every neural signal automatically qualifies as biometric personal data under Article 11. Its classification depends on its characteristics and whether it is used to identify an individual. Health-related neural information may nevertheless fall within the special-category provisions of Article 10.

Example: A Russian company sells a neural monitoring service to customers. It subsequently shares identifiable neural information with a commercial advertising company.

The transaction may raise questions concerning:

The legal basis for collecting the information.

Whether the required consent was obtained.

Whether the purpose of processing was properly disclosed.

Whether the subsequent transfer was lawful.

Whether confidentiality and security obligations were satisfied.

7. Regulation of biohybrid cellular products

Federal Law No. 180-FZ of 23 June 2016, concerning biomedical cellular products, provides another important regulatory foundation.

It covers the development, preclinical research, clinical trials, examination, state registration, production, quality control, sale, application, storage, transportation and export of biomedical cellular products intended for specified medical purposes.

It also regulates biological-material donation for producing these products.

CIS Legislation+1

This legislation is relevant when biohybrid technologies contain biological cellular components.

For example:

Engineered neuronal cell products.

Biological materials combined with medical devices.

Cellular technologies intended for neurological treatment.

Experimental biological components used in regenerative medicine.

However, the statute does not automatically cover every neural organoid, biological computing experiment or biohybrid research platform. Its scope depends on the statutory definition, intended medical purpose and relevant exclusions.

Production of regulated biomedical cellular products also involves licensing requirements. Roszdravnadzor has supervisory responsibilities in this area.

18reg.roszdravnadzor.ru+1

8. Prohibition on commercializing human organs and tissues

The Russian Law of 22 December 1992 No. 4180-I on the transplantation of human organs and tissues establishes an important limitation on biological commercialization.

Its Article 1 provides that human organs and tissues cannot be objects of purchase and sale. Their transplantation is subject to statutory medical and humanitarian requirements.

CIS Legislation+1

This principle is relevant to biohybrid markets because companies may attempt to commercialize biological materials used in neural technology.

Consider three situations:

An important distinction must be maintained: a lawful contract for research services or a registered cellular product is not automatically equivalent to the prohibited commercial sale of human organs or tissues.

9. Intellectual property and commercial contracts

The Russian Civil Code provides the framework for intellectual-property rights and commercial transactions.

Biohybrid businesses may seek protection for:

Neural-interface software.

Brain-computer interface algorithms.

Medical-device engineering.

Artificial intelligence systems.

Biological manufacturing techniques.

Technical processes for integrating biological cells with electronic systems.

However, commercial ownership must be separated into different categories.

Company rights: A company may hold rights over qualifying software, technical inventions, manufacturing processes and devices.

Researcher rights: Researchers and inventors may have rights under applicable employment, patent and intellectual-property rules.

Patient rights: Patients retain legally protected interests in their bodies, privacy, medical information and personal dignity.

A company cannot use intellectual-property ownership as a justification for overriding a patient's lawful refusal of medical intervention or for claiming ownership of the patient's consciousness.

10. Market competition and consumer protection

Commercial biohybrid consciousness technologies may create new market risks.

Suppose one company develops a proprietary neural implant and controls the software necessary for its operation.

Potential problems include:

Exclusive control over implant-compatible software.

Excessive subscription fees.

Unfair restrictions on switching service providers.

Misleading claims concerning cognitive enhancement.

Unauthorized collection of neural information.

Unreasonable contractual limitations on patient rights.

Russian competition law, particularly Federal Law No. 135-FZ of 26 July 2006 on the Protection of Competition, may become relevant where the conduct satisfies its requirements.

The Consumer Protection Law No. 2300-I of 7 February 1992 may also apply to qualifying consumer transactions.

A company marketing a neural enhancement device must not assume that describing it as an ordinary consumer product removes applicable medical or safety obligations.

11. Important case laws and judicial precedents

There is currently no established Russian judicial doctrine specifically recognizing or regulating a commercial market in biohybrid consciousness.

Nevertheless, several actual judicial decisions provide useful legal principles.

Case 1. Constitutional Court of Russia, Judgment No. 1-P of 13 January 2020

Direct Russian constitutional precedent

Subject: Access to medical records of deceased patients.

The Constitutional Court examined the relationship between medical confidentiality, access to medical records and the interests of surviving family members.

The Court found constitutional problems in the uncertainty of the applicable legal framework governing access to the deceased patient's medical records.

It held that, pending legislative clarification, relevant relatives and persons identified in the patient's informed consent should be provided access to medical documents upon request, unless the patient had expressed a prohibition on disclosure during their lifetime.

Relevance to biohybrid consciousness regulation:

This judgment is important for neural technology companies because neural records may contain highly sensitive information about an individual's mental and physical condition.

It demonstrates that medical information requires legal protection even after the patient's death.

Legal principle: Medical confidentiality and access to personal medical information must be balanced through clear legal rules.

ksrf.ru

Case 2. Constitutional Court of Russia, Determination No. 1239-O of 29 April 2026

Direct Russian judicial decision

Subject: Informed consent to medical intervention.

The Constitutional Court considered a complaint concerning Article 20(1) of Federal Law No. 323-FZ.

The Court explained that informed consent must be based on accessible and sufficiently complete information about the purposes, methods, risks, alternatives and consequences of medical intervention.

It rejected the complaint in the circumstances of the case, where the courts had established that consent had been obtained after the patient had been informed about the treatment plan.

Relevance:

A company developing neural implants or biohybrid medical systems should not rely on vague or excessively broad consent documents.

Consent should explain the nature of the procedure and its material risks.

Legal principle: Medical consent must be informed and meaningful, rather than merely formal.

ГАРАНТ

Case 3. Sablina and Others v. Russia, Application No. 4460/16

Communicated application, not a merits judgment

Court: European Court of Human Rights.

Subject: Removal of organs from a deceased person's body.

The applicants complained about the removal of organs from their deceased relative and the absence of an adequate opportunity for the family to express its views.

The application was communicated to the Russian Government on 21 September 2016. The issues raised included Articles 3, 6 and 8 of the European Convention on Human Rights.

The case raised questions about the clarity of Russian organ-transplantation rules and protection against arbitrary interference with private and family life.

Global Health Rights+1

Relevance to biohybrid consciousness markets:

The case illustrates the importance of legal safeguards when biological materials are obtained, retained or used for scientific and medical purposes.

It is relevant by analogy to disputes involving neural tissue, biological samples and research commercialization.

However, it should not be described as a final judicial ruling establishing a legal principle about biohybrid consciousness.

Case 4. Eduard Shabalin v. Russia, Application No. 1937/05, Judgment of 16 October 2014

Court: European Court of Human Rights.

This case concerned the applicant's complaints about detention and related procedural matters.

It is not a neural-technology or biohybrid commercialization case. Consequently, it does not establish a direct precedent on the ownership or commercialization of consciousness.

It should not be relied upon as substantive authority for biohybrid-market regulation.

HUDOC

Case 5. Russian medical-consent litigation, Determination No. 3475-O of 25 December 2025

Subject: Medical intervention and informed consent.

The Constitutional Court's determination is referenced in subsequent Russian judicial proceedings concerning Article 20 of Law No. 323-FZ.

The relevant principle is that medical intervention requires appropriate informed consent, with information about its purpose, methods and risks.

This principle is particularly significant when experimental neural technologies are used on patients.

Relevance: Consent to a therapeutic procedure should not be treated as unrestricted permission for unrelated commercial experimentation.

sudact.ru+1

Case-law limitation: These decisions provide applicable or analogous principles, not a body of Russian judgments directly deciding whether a biohybrid system possesses consciousness or can be traded as a commercial asset.

12. Criminal liability for unlawful biohybrid commercialization

The Russian Criminal Code may apply where biohybrid technology is used for unlawful medical, biological or commercial activities.

Relevant provisions include:

The precise offence depends on the conduct, applicable statutory elements, intent and evidence.

Illustrative scenario:

A biotechnology company operates an experimental neural laboratory. It collects biological samples without appropriate authorization, processes identifiable neural information unlawfully and markets an unregistered medical product.

Possible consequences include:

Regulatory enforcement.

Civil compensation for harm.

Administrative penalties.

Criminal investigation where the elements of an offence are established.

Suspension or prohibition of unlawful activities.

Importantly, the mere development of experimental neural technology is not automatically a criminal offence.

13. Major legal challenges

A. Consciousness ownership

The law must distinguish between ownership of a technological device and the legal protection of the person whose biological system interacts with that device.

B. Commercial exploitation of thoughts

Neural data may reveal sensitive information about emotions, intentions, neurological conditions and cognitive responses.

Commercial exploitation without an appropriate legal basis can create serious privacy and data-protection problems.

C. Biohybrid market monopolies

Companies controlling essential neural-interface technologies could create commercial dependency through proprietary software, exclusive service arrangements and restricted interoperability.

D. Artificial consciousness claims

A manufacturer might advertise a biohybrid product as possessing artificial consciousness.

Such claims create questions about scientific evidence, consumer protection, product safety and the legal status of the technology.

Importantly, a claim that a biological computing system is conscious does not itself establish that it has legal personality or human rights.

E. Biological experimentation

Research involving living human neural tissue raises questions concerning:

Donor consent.

Research ethics.

Biological-material ownership.

Laboratory safety.

Scientific oversight.

Commercial research agreements.

F. Cross-border commercialization

A Russian company might transfer neural data or biological research materials to foreign commercial partners.

Such transactions may involve Russian personal-data rules, medical confidentiality, export requirements and applicable international agreements.

14. Regulatory authorities in Russia

Several authorities may have responsibilities depending on the nature of the technology.

No single Russian authority currently regulates every aspect of biohybrid consciousness markets.

15. Recommendations for a future Russian regulatory framework

Russia could consider developing a dedicated legal framework addressing the following areas.

1. Definition of biohybrid consciousness technologies

Legislation should distinguish between neural implants, brain-computer interfaces, biological computing, neural organoids and genuinely demonstrated consciousness-related systems.

2. Neural-data ownership and protection

The law should clarify the relationship between personal-data rights, medical confidentiality, research rights and commercial licensing.

3. Mandatory informed consent

Separate consent should be required where appropriate for medical treatment, experimental research, neural-data processing and commercial reuse.

4. Commercial licensing

High-risk biohybrid products should be subject to appropriate registration, safety assessment and regulatory oversight.

5. Protection against exploitation

Commercial contracts should not permit coercive experimentation, unauthorized neural-data exploitation or the unlawful sale of human biological materials.

6. Independent scientific oversight

Research institutions should establish independent ethical and scientific review mechanisms.

7. Product liability

Manufacturers and operators should have clearly defined responsibilities for defective implants, unauthorized stimulation, software failures and foreseeable neurological harm.

8. Consciousness-related legal safeguards

Future legislation could examine whether additional protections are necessary where technologies can significantly alter, monitor or manipulate cognitive functions.

16. Hypothetical legal case studies

The following examples illustrate how Russian law might apply. They are hypothetical, not reported judgments.

17. Conclusion

Biohybrid Consciousness-Market Regulation in Russia represents a developing legal challenge at the intersection of biotechnology, artificial intelligence, medical law, constitutional rights, commercial regulation and intellectual property.

The existing Russian legal framework already provides important safeguards through:

Constitutional protection of human dignity and privacy.

Informed medical consent under Federal Law No. 323-FZ.

Personal-data protection under Federal Law No. 152-FZ.

Biomedical cellular-product regulation under Federal Law No. 180-FZ.

Restrictions on the commercial sale of human organs and tissues under Law No. 4180-I.

Civil and criminal liability for unlawful commercial and medical conduct.

However, these laws do not comprehensively resolve the distinctive legal questions raised by technologies combining living neural systems with artificial intelligence and commercial infrastructure.

The central legal principle is that commercial ownership of biohybrid technology must not be confused with ownership of human consciousness, personal identity or dignity.

Russia may therefore need a specialized regulatory framework to balance scientific innovation, legitimate commercial activity, medical safety and fundamental human rights.

18. Important legal references and research sources

Federal Law No. 323-FZ – Russian Healthcare Protection Law.

Federal Law No. 152-FZ – Personal Data Protection.

Federal Law No. 180-FZ – Biomedical Cellular Products.

Russian Civil Code – Article 128.

Law No. 4180-I – Human Organ and Tissue Transplantation.

Constitutional Court Judgment No. 1-P of 2020.

Constitutional Court Determination No. 1239-O of 2026.

Sablina and Others v. Russia – ECHR Application No. 4460/16.

Research note: This is an academic legal analysis, not legal advice. Russia ceased to be a party to the European Convention on Human Rights on 16 September 2022; the Convention's temporal jurisdiction must therefore be considered when using ECHR cases involving Russia.